how many people use glp-1 drugs trends 2025: real-world data, patient outcomes & future therapies This is the worst the
Description
Key Report Takeaways By mechanism of action, GLP-1 receptor agonists led with 38.55% of the anti-obesity drugs market share in 2025
Researchers documented striking results in this trial
Similarly, GLP-1 receptor agonist use was associated with an increased risk of suicidality compared with SGLT-2 inhibitors in crude analyses (crude incidence rates 4.3 v 2.7 per 1000 person years
Use features like bookmarks, note taking and highlighting while reading The Ultimate GLP-1 Cookbook: Eating Well For Weight Loss Success.
